Azizi Ray
Researcher
Also affiliated: Mercer University (2018–2019); University of New Mexico (2025); Mercer University Health Sciences Center (2018–2020)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Azizi Ray's research focuses on substance abuse treatment, particularly the use of gabapentin as an adjunct during outpatient buprenorphine tapering for opioid use disorder. Ray has investigated the impact of fentanyl on treatment outcomes within this protocol and explored gabapentin's role during the taper and transition to injectable naltrexone in a randomized, placebo-controlled trial. This work contributes to understanding pharmacological interventions for opioid use disorder and its management.
Ray has authored 10 publications and has an h-index of 4 with 95 citations. Key collaborators include Michael J. Mancino, Alison Oliveto, J. Benjamin Guise, and Jeff D. Thostenson, all from the University of Arkansas for Medical Sciences, with whom Ray has co-authored multiple publications.
Metrics
- h-index: 4
- Publications: 10
- Citations: 95
Selected Publications
-
Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone (2025)
-
THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN (2024)
Collaboration Network
Top Collaborators
- THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN
- Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone
- THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN
- Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone
- THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN
- Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone
- THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN
- Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone
- THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN
- Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone
- Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone
Similar Researchers
Based on overlapping research topics